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Abstract
Lung cancer is the number one cause of cancer related death worldwide, with more than
1.6 million fatalities each year. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all
lung cancers, with KRAS being one of the most prevalent oncogenic driver mutations.
Therapeutic approaches for KRAS-mutated NSCLC have been extensively explored due to the
US National Cancer Institute RAS Initiative, but methods of directly targeting KRAS or
downstream effectors, such as MEK, still have poor results. Previous reports have shown that
KRAS-mutated NSCLC activate distinct receptor tyrosine kinases (RTKs) depending on the
epithelial or mesenchymal state. Epithelial-to-mesenchymal transition (EMT) is known to play a
role in the metastasis and poor prognosis of cancer, and is induced by extracellular matrix
(ECM) stiffness. Hallmarks of EMT include loss of E-Cadherin and increase in Vimentin. This
research investigates the role of KRAS in EMT transition due to increased ECM stiffness in
KRAS mutant NSCLC, and how this affects the efficacy of KRAS and MEK inhibition. To
understand how KRAS mutations in NSCLC play a role in this stiffness induced EMT,
experiments were performed to detect the gene and protein expression of EMT markers, as well
as possible sources of mechanosensing, including primary cilia and receptor tyrosine kinases.
We hypothesized that KRAS plays a role in activation of mechanosensors and directly
correlates to EMT induced by increased mechanical forces. Results show when KRAS was
inhibited and there was increased mechanical forces, either from stretch or substrate stiffness,
there was a decreased activation of mechanosensors. KRAS inhibition also prevented the cells
from undergoing stiffness-induced EMT. This supports our hypothesis that KRAS plays a key
role in ECM stiffness induced EMT. Future studies include examining the mechanism behind
this phenomenon and in vivo studies.
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Introduction
Lung Cancer
Lung cancer is the number one leading cause of cancer related deaths, with more
people dying from lung cancer than colon, breast, and prostate cancer combined. Lung cancer
is the most common cancer worldwide, and according to the American Cancer Society 234,030
new cases of lung cancer will be diagnosed in 2018. Approximately 80% of lung cancer deaths
are due to tobacco smoking [1]. Although lung cancer is more common in smokers, there are
non-smokers who develop lung cancer, which can be caused by mutations in DNA that leads to
up-regulation of oncogenes or down-regulation of tumor suppressor genes. There are two main
types of lung cancer: small cell lung cancer (SCLC), which accounts for 10-15%, and non-small
cell lung cancer (NSCLC), which accounts for 80-85% [1].

NSCLC
There are multiple types of NSCLC, but they are grouped together since treatment is
similar. Adenocarcinoma, which accounts for 40% of all lung cancer, is found in the outer parts
of the lung, in cells that line the alveoli and would normally secrete mucus. Adenocarcinoma is
the most common type of lung cancer that occurs in non-smoking patients, as well as younger
patients. Squamous cell carcinoma accounts for 25-30% of all lung cancers. It is found in the
central part of the lung, in squamous cells that line the passages from the trachea to the
bronchi. Large cell carcinoma accounts for 10-15% of all lung cancer, and is found in epithelial
cells that line the lung [1, 2]. Tradition treatment options include surgery, chemotherapy, and
radiation, however survival rates remain low. New strategies such as immunotherapy, and
targeted therapy are currently being explored.
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NSCLC KRAS Mutations
DNA mutations in genes that control
cell proliferation, differentiation, and cell
death can initiate a cancer phenotype.
These driver mutations in oncogenes cause
oncogenesis, and can allow for sustained
proliferative signaling, evasion of growth
suppressors, resistance to apoptosis,
and increased invasion. Cancer cells

Figure 1: Most common genetic mutations in NSCLC. Pie chart
showing percentage of lung cancer with genetic mutations, with
KRAS, EGFR, and ALK being the most prevalent [3].

are dependent on the activity of specific oncogenes, and the development of targeted therapies
has allowed for the inactivation of these genes. Many oncogenic driver mutations have been
detected in NSCLC, with Kirsten Rat Sarcoma (KRAS) being the most prevalent, as shown in
Figure 1 [3].

Figure 2: RAS signaling pathways. RAS pathways include MAPK, PI3K, and Ral, which initiate differentiation,
proliferation, cell survival, and cell cycle [4].
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RAS is the most frequently mutated gene family in cancer. It encodes small enzymes
that hydrolyze guanosine triphosphate (GTPases) and activate various signaling pathways,
which can been seen in Figure 2 [4]. Activation of the RAS protein occurs when hormones bind
to cell-surface receptors. Guanine nucleotide exchange factor (GEF), which is bound to RAS,
accelerates this activation. This activation process causes the dissociation of guanosine
diphosphate (GDP) and allows guanosine triphosphate (GTP) to bind spontaneously to RAS,
releasing GEF. Hydrolysis of GTP occurs with the assistance of GTPase-activating protein
(GAP) causing the deactivation of RAS. The cycling of RAS between active and inactive forms
can be seen in Figure 3 [5]. When RAS is mutated it can no longer hydrolyze GTP and is now

A

B

permanently stuck in the “on” state.
Mutations tend to be single
base substitutions that lead to
stabilization of GTP binding and cause
up-regulation of cell proliferation,
differentiation and survival [6]. The
most common mutations in KRAS are

Figure 3: Cycling between inactive RAS-GDP and active RAS-GTP.
With the assistance of GEF and GAP, RAS cycles between active and
inactive forms. A. Normal cells maintaining homeostasis. B. Cancerous
cells with a mutation in RAS causing RAS to be stuck in the RAS-GTP
state and the development of oncogenesis [5].

G12C, G12V, G12D and G12A. It
has been shown that mutations in
codon 12 lead to increased

resistance to apoptosis, loss of contact inhibition, and predisposition to anchorage-independent
growth compared to the other KRAS mutations in codon 13 or codon 61 [7]. It has also been
shown that KRAS mutation G12A activates PI3K and MEK signaling, while G12C and G12V
mutations activates Ral signaling [8]. In NSCLC, mutations and rearrangements in EGFR,
BRAF, HER2, ALK, ROS, and RET have been used as biomarkers for targeted therapies, yet
anti-RAS therapies have been unsuccessful [8].
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In order to study KRAS mutated NSCLC in-vitro, immortalized cell lines were created by
extracting lung cancer tissue from patients. Since these cancer cells have evaded normal
cellular senescence, they are able to continually undergo division and be cultured for prolong
periods of time [9]. NCI-H1792 cells were derived from a 50 year old male patient with G12C
KRAS mutated adenocarcinoma from an unknown date or creator. NCI-H358 cells were derived
from a male patient of unknown age with G12C KRAS mutated bronchioalveolar carcinoma in
1981 by A.F. Gazdar before the treatment of chemotherapy [10]. LU99 cells were derived from a
63 year old male patient with G12C KRAS mutated lung giant cell carcinoma in 1986 by S.
Hirohashi [11]. NCI-H441 cells were derived from a 33 year old male patient with G12V KRAS
mutated papillary adenocarcinoma; it is unknown when or by whom this line was created [12].
These cell lines are widely used for studying NSCLC and have been confirmed to have KRAS
mutations [13].

Lung Mechanics
The lungs undergo many different physical forces, from surface tension at the air-liquid
interface, pressure generated stretch and shear strain from blood flow, bilateral tensile stress
during inhalation, and compressive forces during exhalation. Studies have shown that lung cells
experience up to a 30% change in
surface area during respiration [14].
These normal physical forces impact the
structure and function of the lung. It has
been shown that cells can sense these
forces, and this stimulation can activate
intracellular signaling and regulate gene
Figure 4: Lung mechanoreceptors. Activated by mechanical
stretch, including stretch activated calcium channels, protein
tyrosine kinases, and integrins, and initiate of signaling pathways,
including MAPK, DAG, and IP3 [15].

expression. Specifically, it has been
shown that normal mechanical force
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stimulates growth factor production, fibers for ECM formation, and permeability of pulmonary
endothelial cells [15].
There are different mechanism for which lung cells sense mechanical force, as shown in
Figure 4 [15]. Stretch receptors, which are located on the smooth muscle layer of the pulmonary
airways, activate due to stretch from inhalation and send action potentials through the vagus
nerve. These mechanoreceptors are involved in neural regulation of respiratory frequency and
bronchial blood flow [16]. Stretch-activated calcium channels have also been found in lung cells.
These channels respond to changes in tension, thickness, or curvature in the lipid bilayer and
alter their conformation from open or closed state, which allows for ions to flow through [17, 18].
Primary cilia sense mechanical loading and initiate remodeling in the lung. Integrins, a type of
heterodimeric transmembrane receptors, are another method for mechanotransduction in the
lung. Integrins connect the extracellular matrix (ECM) with intracellular actin fibers in the
cytoskeleton, sense mechanical forces from the ECM, and transmit them through the
cytoskeleton to the inner cell [19]. Protein kinases can detect mechanical stimulation, activating
secondary messengers to alter intracellular signaling. For example, mechanical strain led to
increased Protein kinase A and Protein kinase C activity in lung cells [20, 21]. Protein tyrosine
kinases, a type of protein kinase that phosphorylates tyrosine amino acid residues, and
serine/threonine-specific protein kinases have also been reported to have increased activity due
to mechanical strain in lung tissue [22, 23].

Primary Cilia
Primary cilia are immotile microtubule-based sensory organelles that are found on nearly
every mammalian cell and are known to sense mechanical stimulation and initiate intracellular
signaling pathways. Primary cilia consist of nine doublet microtubules that are derived from the
centriole of the centrosome, which are linked by Nexin, and surrounded by a membrane, which
is an extension of the cellular membrane, as seen in Figure 5 [24]. Primary, or immotile cilia,
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differ from motile cilia in that
they cannot move due to the
lack of another central pair of
microtubules, as well as inner
and outer dynein arms. Unlike
motile cilia, primary cilia are
mostly short in length, with
some not projecting beyond
the surface of the cell. Primary
cilia are formed during
interphase of the cell cycle,

Figure 5: Primary cilia structure. Including cilia membrane, doublet
microtubules, and the IFT raft for transport of necessary molecules. The
differing structure of motile cilia is shown underneath, with the addition of
dynein arms, radial spokes, and an extra set of doublet microtubules in the
center [24].

where the centrosome moves to the cell surface and attaches to a Golgi vesicle. The axonemal
microtubules polymerize and grow above the centriole, gaining the building blocks they need in
a process known as intraflagellar transport (IFT) [25].
When mechanical forces cause the primary cilium to bend, signaling that results in cell
migration, differentiation, and proliferation can become activated. Primary cilia can be involved
in multiple types of signaling and can also activate signaling pathways such as receptor tyrosine
kinases (RTK), Calcium channels, Hedgehog signaling, and ECM signaling. Primary cilia were
first studied as mechanosensors in the kidney; fluid flow caused deflection of primary cilium,
which caused an increase in intracellular calcium. This is believed to be controlled by polycystin1 (PC1) ion channels localized near primary cilia. When primary cilia formation is hindered
polycystic kidney disease results. Primary cilia can also detect fluid flow in the bile duct of the
liver and signal for increase in intracellular calcium, again mediated by PC1 ion channel [25].
It has also been shown that primary cilia are critical mechanosensors in osteocytes in
bone, with this again being linked to PC1 channels [26]. When formation of primary cilia was
blocked, there was a decrease in mechanically induced bone formation. In endothelial cells,
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primary cilia have been found to be located in areas of low stress, suggesting that they allow the
cell to sense smaller mechanical forces. When primary cilia are removed from the endothelial
cells, they are no longer responsive to flow [26]. In cartilage, chondrocytes have primary cilia
that are surrounded by ECM integrins and have been shown to not only sense flow but
compressive forces as well. Primary cilia respond to mechanical stimulation by up-regulation of
proteoglycans, but when primary cilia are removed this up-regulation no longer occurs. It has
also been shown that without primary cilia, chondrocytes no longer organize themselves in the
growth plate [26].

Primary Cilia in the Lung
Primary cilia have been shown to function as mechanosensors in the kidney, liver, bone,
endothelial cells, and cartilage, however not much is known about primary cilia mechanosensing
in the lung. It has been shown that in early development airway, epithelial cells possess primary
cilia, however as they mature they lose primary cilia but can still signal to primary cilia on
mesenchymal cells through sonic hedgehog signaling (SHH) [27]. Primary cilia have also been
linked to sensing mechanical loading and allow for cell contractility, leading to remodeling in
airway smooth muscle cells [28, 29].

Primary Cilia in Cancer
Primary cilium involvement in cancer is a recent concept, and as it is being explored, it
has become clear that primary cilia have different responses in different types of cancer.
Primary cilia are known to house many different oncogenic molecules such as epidermal growth
factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), KRAS, and
Smoothened, and these different molecules can have different effects on primary cilia. In
medulloblastomas, basal cell, and gastrointestinal stromal tumors, it has been seen that primary
cilia are present and contribute to the formation of tumors. In medulloblastomas and human
basal cell carcinoma, it has been shown that deletion of primary cilia inhibited tumors that were
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activated by smoothened protein, but accelerated tumor formation in tumors that were activated
by Gli2, a transcriptional effector of Hedgehog signaling [30]. In many other cancers, it has been
shown that primary cilia are decreased in tumor cells [30, 31].
This comes with two theories, one stating that primary cilia are lost due to the fact that
their formation is linked to the cell cycle and cancer cells are highly proliferative, the other
stating that the lack of primary cilia is completely independent of the proliferation status and that
cancer cells have an existing mechanism to avoid ciliogenesis [32]. In one study, it was
suggested that primary cilia play a role in kinase inhibitor resistance, which is a major issue in
treating genetically defined cancers. Multiple NSCLC cell lines with different mutations, including
EGFR, ALK, and KRAS, were found to have increased number of primary cilia or increased cilia
length with drug resistance compared to parental cell line. In some lines primary cilia were
detected in the parental cell line, but in others there were no primary cilia present [33].

Primary Cilia and KRAS in Cancer
KRAS mutations exist in over 90% of pancreatic adenocarcinoma (PDAC). It has been
shown that there is a loss of primary cilia in PDAC and that when KRAS is inhibited primary cilia
formation is restored [34, 35]. Histone
deacetylase 2 (HDAC2) was also
examined and it was found to function
independently from KRAS to induce
the loss of primary cilia, its
mechanism shown in Figure 6 [34].
Furthermore, depletion of KRAS and
HDAC2 lead to a higher increase of

Figure 6: KRAS and HDAC2 signaling pathways lead to a loss of
primary cilia in PDAC [34].

formation of primary cilia compared to depletion of the genes singularly.
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In cholangiocarcinoma, a cancer derived from the epithelial cells lining the vessels that
direct secretions from the liver and pancreas to the duodenum, it has been shown that there is a
loss of primary cilia linked to the overexpression of histone deacetylase 6 (HDAC6) [36]. HDAC6
deacetylates tubulin in the cilia, leading to resorption. KRAS activates HDAC6, and mutation of
KRAS could lead to increased activation of HDAC6 and loss of primary cilia in these cancers
[36]. The mechanism behind KRAS mutations that cause a gain of primary cilia have not been
explored, though it has been shown in KRAS mutated NSCLC there is an increased presence
[33].

Extracellular Matrix Stiffness
The extracellular matrix (ECM) provides physical scaffolding for the cell. ECM is
composed of proteoglycans (PGs) and fibrous proteins such as collagen, elastin, laminin, and
fibronectin. Collagen, the most abundant protein, is secreted from fibroblasts that are able to
organize and align the collagen through applied tension to the matrix. This network of fibrous
proteins allow the ECM to resist tensile stresses, while hydrated glycosaminoglycans (GAGs)
allow the ECM to resist compressive stresses. Stiffness of the ECM can be increased by the
organization and crosslinking of these fibers, as well as amount of PGs, and posttranslational
modifications [37]. The stiffness of the ECM, or the elastic modulus (E), is measured by the
amount of force, in Newton’s (N), that is required to cause a unit deformation, in square meters
(m2), of the ECM, and ranges depending on tissue type, as seen in Figure 7. In brain tissue the
elastic modulus is 100 N/m2, or Pascal
(Pa), and in the liver E ranges from 300
to 600 Pa. Muscle has a higher E of 12
kilapascals, while tendons and cartilage
Figure 7: ECM stiffness ranges. Normal lung stiffness is in the range
of 1 kPa, whereas the plastic that is normally utilized for tissue culture
is in the 2 GPa range [37].

is in the range of megapascals. This is
not comparable to the stiffness of
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tissue culture plastic, which is in the range of 2-4 gigapascals and is far stiffer than the stiffest
living tissue [37, 38].

ECM Stiffness in Healthy Lung
The pulmonary ECM is composed of thin sheets of glycoproteins, known as the
basement membrane, and a fibrous matrix that allows for connection between cells. Collagen
types I, II, III, V, and XI give the lung its tensile strength, while elastin and fibrillin fibers give it
compliance and elasticity. Alveoli ECM is comprised mostly of type I and III collagens, as well as
elastin [39]. The elastic modulus of healthy lung has been determined to be in the range of 1-5
kPa through atomic force microscopy [37, 38].

ECM Stiffness in Lung Cancer
The ECM of cancerous tissue is stiffer than normal tissue. As seen in Figure 8, this is
achieve through the secretion of growth factors, metalloproteinases, and cytokines, which
stimulate fibroblast migration and proliferation. Fibroblasts then synthesize more fibrous

Figure 8: Healthy vs. cancerous ECM composition. A. Normal ECM remodeling to ensure homeostasis. B.
Cancerous ECM includes activation of fibroblasts, leading to increased ECM production. C. Late stage tumors with
formation of vasculature that facilitates metastasis. D. Distal tumor sites [39].
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proteins, and increase the stiffness and mechanical stress of the ECM. This increased stiffness
causes multiple reactions that allow cancerous cells to propagate. Biomechanical cues from the
ECM, such as stiffening, are transduced through integrins to alter intracellular signaling
controlling homeostasis, cell morphology, proliferation, differentiation, motility, and survival.
Increased ECM stiffness leads to differentiation of the cells and allows for epithelial cells
to transition into mesenchymal cells. While most cells are anchorage dependent, mesenchymal
cells are able to migrate, which can lead to metastasis of cancerous cells. Increased ECM
stiffness can also allow for mesenchymal stem cells to differentiate into myofibroblasts, which in
turn synthesize more ECM, which stiffens the tissue further. This increased stiffness causes
destabilization of cell to cell adhesions and cell-basal membrane adhesions which also allows
for the cells to migrate. Finally, the stiffness causes biomechanical cues that trigger cellular
signaling that increases proliferation and migration. The release of growth factors, such as
vascular endothelial growth factor (VEGF), allows for new vessel formation, which not only
increases interstitial pressure, but also gives the tumor vasculature for survival [37].
Lung cancer ECM has increased levels of specific fibrous proteins including laminin,
collagen IV, fibronectin, and tenascin-C. This alteration in deposition is accompanied by
increased hydroxylysine aldehyde-derived collagen cross-links and decreased lysine aldehydederived cross-links [39]. The stiffness of lung cancer ECM can range from 20-100 kPa [39, 40].

ECM Stiffness and KRAS
As previously mentioned, integrins are one of the main ways through which the cell
senses the forces of the ECM. Integrins create adhesions between the extracellular matrix and
the cytoskeleton of the cell, by binding to matrix fibrils, while associated with intracellular actin
filaments of the cytoskeleton. They transmit these mechanical loads from outside the cell to
inside the cell, which then plays a role in activating intracellular signaling. Mechanical force,
sensed through integrins, is known to activate the RAS-ERK signaling pathway, but little is
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known about the role of KRAS in mechanosensing ECM stiffness. In one study, it was found
that expression of KRAS in lung cancer cells was affected by the ECM stiffness, and that there
was a threshold between 15-28 kPa where KRAS protein levels had a mechano-sensitive
response [41]. It was also found that high levels of KRAS induced a tumorigenic phenotype and
that the migration velocity increased with increased ECM stiffness [41]. In another study
examining cellular metabolism in NSCLC, it was found that KRAS was responsible for
mechano-sensitivity to soft and stiff substrates leading to changes in glycolysis [42]. While
KRAS has been explored in context of integrins, other forms of sensing ECM stiffness in relation
to KRAS have not been extensively explored.

ECM Stiffness-Induced EMT
Epithelial to mesenchymal transition (EMT) occurs when cells with an epithelial-like
phenotype lose their cell-cell adhesion, and apical-basal polarity, and become more
mesenchymal and motile. This is marked by
down-regulation of epithelial proteins
including E-cadherin, and Zonula
Occludens 1 (ZO1), and up-regulation of
mesenchymal proteins including Vimentin,
and N-cadherin. One way EMT can be
Figure 9: ECM stiffness-induced EMT. On the soft matrices
cells have few focal adhesions, growth arrest, and are nonfibrogenic. As the matrix stiffened, cells have increased focal
adhesions, proliferation, and fibrogenesis [38].

initiated is by increased stiffness of the
ECM due to changes in the organization and

crosslinking of the collagen fibers, as seen in Figure 9 [38]. EMT plays a large role in cancer
progression in that it allows the cancerous cells to detach from the primary site and migrate to
other tissues. There is also evidence to suggest that EMT is the cause of primary and acquired
drug resistance in many cancer types, including NSCLC. In breast cancer it has been shown
that KRAS activation was necessary for cells to transition to mesenchymal phenotype and have
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metastatic ability [43]. In colorectal and pancreatic cancer cells it was found that KRAS
expression induced expression of mesenchymal genes, such as Vimentin, and reduced the
expression of epithelial genes, such as E-cadherin [44].

Receptor Tyrosine Kinase
Receptor Tyrosine Kinases (RTKs) are a family of cell surface receptors, that when
bound to extracellular signaling molecules, such as growth factors, initiate intracellular signaling
pathways involved in proliferation, differentiation and motility. There are 58 RTKs, comprised of
an extracellular binding domain, a transmembrane helix, and an intracellular tyrosine kinase
domain. RTK activation leads to
activation of the MAPK pathway through
the recruitment of RAS, as shown in
Figure 10. The most commonly mutated
RTKs in NSCLC include EGFR, ErbB2,
DDR2, ALK, RET, MET, FGFR1, and
PDGFRα [46].
RTKs are physically part of the
Figure 10: RTK activation. Occurs through ligand binding, induces
RAS signaling pathway, causing upregulation of proliferation, cell
migration, and survival [45].

mechanosensing integrin complex. For
example, insulin-like growth factor

receptor (IGFR-1), VEGF2, and PDGFR are associated with αvβ3 integrin, and EGFR, c-Met,
and ErbB2 are associated with α6β4 [47]. It has been shown that some RTK, such as EGFR
can be directly activated by integrin activation. Not only can RTKs be activated through ECM
stiffness-dependent activation of integrins, but they also regulate the activity of the integrin
complex. They also can act independently of the integrin complex. This was confirmed by a
study that seeded cells on micro-fabricated pillars and used fluorescence microscopy to observe
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the mechanism of mechanosensing. It was found that when RTKs such as AXL and ROR2 were
directly inhibited, the mechanosensing activity of the cell was altered [48].
Understanding the role of KRAS in mechanosensing in NSCLC could potentially open
new doors for therapeutic options in a subset of cancers that has a poor prognosis. NSCLC is
known to be an aggressive form of cancer with the ability for EMT, metastasis and invasion, and
mechanosensing forces may be propagating these characteristics. Our goal is to determine if
KRAS is playing a role in mechanosensing of the surrounding environment. Primary cilia and
receptor tyrosine kinases are some of the main mechanosensing mechanisms, and are known
to interact with KRAS. We hypothesize that the activation of these mechanoreceptors through
mechanical forces is directly affected by KRAS, and this phenomenon may lead to increased
mesenchymal phenotype.

Objectives
1. To identify if KRAS plays a role in mechanosensing stretch in NSCLC
a. Identify the presence of primary cilia in KRAS mutated NSCLC
b. Identify the effect of stretch on the presence of primary cilia in KRAS mutated
NSCLC
c. Use Trametinib to determine the effect of inhibiting MEK on the presence of
primary cilia in KRAS mutated NSCLC under static conditions
d. Use short hairpin RNA (shRNA) to target and silence the gene expression of
KRAS in order to determine the role of KRAS in presence of primary cilia in
KRAS mutated NSCLC under static and stretched conditions
2. To identify if KRAS plays a role in mechanosensing of ECM stiffness in NSCLC
a. Identify the key receptor tyrosine kinases that are activated through
phosphorylation in the presence of normal and cancerous ECM stiffness through
RTK array analysis
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b. Use ARS1620 to inhibit KRAS and Trametinib to inhibit MEK to determine the
role of KRAS in RTK stiffness activation
c. Confirm the stiffness-induced activation of RTKs and the result of inhibiting
KRAS and MEK through western blotting
3. To identify if KRAS mutation is effecting EMT in NSCLC
a. Use RT-qPCR to examine gene expression of epithelial and mesenchymal
markers and identify the effect of KRAS by using short hairpin RNA (shRNA) to
target and silence the gene expression of KRAS
b. Confirm the protein expression of epithelial and mesenchymal markers through
western blotting and identify the effect of KRAS by inhibiting with ARS1620 and
the effect of MEK by inhibiting with Trametinib

Materials and Methods
Cell Culture
Human lung giant cell carcinoma LU99 (RRID: CVCL_3015), bronchioalveolar carcinoma NCIH358 (ATCC® CRL-5807™), papillary adenocarcinoma NCI-H441 (ATCC® HTB-174™), and
adenocarcinoma NCI-H1792 (ATCC® CRL-5895™) were used to perform experiments.
Mutation status of cell lines used was obtained from the Cancer Cell Line Encyclopedia (CCLE).
Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (GIBCO, Grand
Island, New York) with 10% Fetal Bovine Serum (FBS) (GIBCO, Grand Island, New York) and
1% Penicillin/Streptomycin (GIBCO, Grand Island, New York), unless otherwise stated. Cells
were grown in 100 mm tissue culture dishes until 70-80% confluency, washed with phosphate
buffered saline (PBS) (GIBCO, Grand Island, New York), then trypsinized with Trypsin-EDTA
(0.25%) (GIBCO, Grand Island, New York) and passaged. The cells were incubated at 37 °C,
with 95% air, and 5% CO2. Prior to seeding cells for experiments, 6 well BioFlex plates, SoftWell
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plates, and 6 well tissue culture plates were coated with 1 mL of 0.1mg/mL rat tail Collagen
Type I (Sigma-Aldrich, St. Louis, MO) diluted in sterile 50mM HEPES for 1 hour at biological
conditions. Trametinib, known also by the trade name Mekinist, is an allosteric MEK1/MEK2
inhibitor that has been FDA approved for NSCLC and Melanoma in combination with Tafinlar, a
BRAF inhibitor. Trametinib was obtained from Selleckchem, dissolved in DMSO, and used at a
concentration of 1μM. ARS1620 is a promising atropisomeric selective KRAS G12C inhibitor.
ARS1620 was obtained from MedChemExpress, dissolved in DMSO, and used at a
concentration of 1μM.

Tet-ON shRNA
H441 cells were transduced with a plasmid containing a tetracycline-inducible promoter
upstream of the KRAS gene and a reverse tetracycline-controlled transactivator. Cells were
treated with 1μg/mL puromycin for 3 days to select infected cells, and expression of shRNA was
induced by growing cells in the presence of 50 ng/mL doxycycline for 72 hours.

Cell Stretch
LU99, NCI-H358, and NCI-H441 cells were plated in 6-well BioFlex culture dishes at a density
of 300,000 cells/well, and the next day serum starved in RPMI medium supplemented with 1%
FBS and 1%
Penicillin/Streptomycin for 24
hours. After 24 hours, the
medium was switched to RPMI
supplemented with 10% FBS
and 1%
Penicillin/Streptomycin. Static
cells were drugged with 1μM
Figure 11: FlexCell Tension Plus System [74].
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Trametinib for 48 hours. Cell were stretched to a maximum of 15% change in membrane
surface area at 0.86 Hz for 48 hours. Stretch was performed using the FlexCell Tension Plus
system (Flexcell International Corporation, Hillsborough, NC), shown in Figure 11. This system
has a 25mm loading station and uses vacuum pressure to apply equibiaxial stress to the cells
that have been plated on the silicone membrane 6-well dishes, shown in Figure 12. After
stretch, plates are removed for analysis.

Figure 12: Equilateral tension applied to cells through
FlexCell Tension Plus System [74].

Immunofluorescence
Cells were fixed using 4% Paraformaldehyde solution, permeabilized with 0.2% Triton X-100
and blocked with 5% bovine serum albumin. The cells were stretch on a silicone membrane 6well dish; before incubating the fixed cells in antibody each silicone membrane was excised
from the plate using a scalpel and three small pieces from different parts of the membrane were
transferred to a 24-well dish and incubated with primary antibodies overnight at 4°C. One well
was kept hydrated with blocking buffer and no primary antibody was added. Sigma T7451
mouse anti-acetylated tubulin was used at a dilution of 1:500 (Sigma-Aldrich, St. Louis, MO),
and rabbit anti-ARL13B was used at a dilution of 1:100 (Proteintech, Chicago, IL). Primary
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antibody was removed and the membranes were washed three times with PBS-tween.
Secondary antibody was added and incubated for one hour, including the well that was not
treated with primary antibody as a control for background activity. Secondary antibody goat antimouse Alexa Fluor 488 was used at a dilution of 1:800 (Life Technologies, Grand Island, NY)
and goat anti-mouse Rhodamine-conjugated IgG was used at a dilution of 1:100 (Proteintech,
Chicago, IL). After incubation, the fixed membranes were washed again three times with PBStween and samples were mounted on slides using Prolong gold anti-fade reagent with DAPI
(Life Technologies, Grand Island, NY). Z-stack images at 40X were taken with scanning
confocal microscope Zeiss LSM 700 and analyzed using Zen image analysis software.

Protein Isolation from varied stiffness plates
Cells were cultured on Matrigen Softwell 6-well dishes of 1 kPa and 25 kPa for 72 hours. Cells
were drugs with 1μM of ARS120 and Trametinib for 48 hours. Media was removed from the
wells, collected in 15 mL tubes, and centrifuged at 1,500 RPM for 10 minutes at 4°C. The dishes
were put on ice, and 90μL of ice-cold NP-40 lysis buffer containing a protease inhibitor cocktail
was added to the wells. The cells were removed from the well with a cell scraper and collected
in an Eppendorf tube. After centrifugation of the media, the supernatant was removed and the
cell pellet was suspended in 10μL of lysis buffer and transferred to the Eppendorf tube with the
scraped cells. Lysates were allowed to incubate on ice for 30 minutes and subsequently
centrifuged at 14.8 RPM for 15 minutes at 4°C, with the supernatant being transferred to a new
tube and the pellet being discarded.

Human Phospho-RTK Array
After protein was collected, Pierce™ bicinchoninic acid (BCA) assay kit (ThermoFisher
Scientific, Waltham, MA) was used to determine the amount of protein obtained, using bovine
serum albumin (BSA) as a protein standard. Proteome Profiler Human Phospho-Receptor
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Tyrosine Kinase Arrays (R&D Systems, Minneapolis, MN) were incubated in Array Buffer 1 for 1
hour at room temperature. 300μg of protein from cell lysates was diluted to a final volume of 1.5
mL with Array Buffer 1 and incubated on the array membranes overnight at 4 °C. Arrays were
washed with 1X Wash Buffer, then incubated with Anti-Phospho-Tyrosine-HRP for 2 hours at
room temperature. SuperSignal West Femto electrochemiluminescent reagents were used to
image membranes on a G:BOX Chemi high resolution gel imager. ImageJ was used to
determine average particle density and compare relative change in tyrosine phosphorylation of
specific RTKs between samples.

Immunoblotting
NuPAGE® 10X Sample Reducing Agent and 4X LDS Sample Buffer (Invitrogen, Carlsbad, CA)
were used to denature proteins and reduce disulfide bonds, with 25μg of protein being used for
each sample. The mixture was heated at 75°C for 10 minutes and loaded onto precast 4-12%
polyacrylamide NuPAGE® Bis-Tris Gels (Invitrogen, Carlsbad, CA) with NuPAGE® MOPS SDS
running buffer (Invitrogen, Carlsbad, CA) diluted to a 1X concentration with deionized water.
Electrophoresis was performed at 150V in a Bio-Rad Criterion Midi-Cell in order to separate
proteins based on molecular weight, with Precision Plus Protein™ Dual Color Standards
(BioRad, Hercules, CA) being used to estimate the location of molecular weights on the gel.
After completion of electrophoresis, the proteins on the gel were transferred onto a
polyvinylidene difluoride membrane in a transfer chamber with Tris-glycine buffer, using 1 Amp
for 1 hour. Membranes were blocked with 5% milk for 1 hour to avoid binding of non-specific
proteins. Primary antibodies directed against the following were obtained from Cell Signaling
Technology and were used at a concentration of 1:1000 in 5% BSA and incubated on the
membrane overnight at 4°C: Phospho-IGF-I Receptor β (Tyr1131)/Insulin Receptor β (Tyr1146)
(#3021S), phospho-EGF Receptor (#3777S), phospho-MET Y1234/1235 (#3126S), phosphop44/42 MAPK T202/204 (#4370S), and beta-actin 13E5 (#4970S). K-Ras (F234), E-Cadherin
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(G-10) and Vimentin (V9) were obtained from Santa Cruz Biotechnologies and used at a
concentration of 1:1000. Secondary horseradish peroxidase donkey anti-rabbit IgG was used at
1:10,000 and anti-mouse at 1:2,000, diluted in 2.5% milk, and incubated at room temperature
for 1 hour. SuperSignal West Femto electrochemiluminescent reagents were used to image
membranes on a G:BOX Chemi high resolution gel imager.

RNA Isolation and Real-time quantitative PCR
RNA was collected and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). Following
protocol for the kit, 600μL of RLT buffer was used to lyse RNA, which was collected in an
Eppendorf tube and centrifuged at 10,000 rpm for 30 seconds. An equal volume of 70% ethanol
was added to the lysis and vortexed. The mixture was transferred to a RNeasy mini spin column
and RW1 and RPE buffer were used to purify the RNA solution. Using 30μL of Rnase-free
water, the RNA was collected from the mini spin column. The RNA was then converted to cDNA
through reverse transcription using iScript™ cDNA Synthesis Kit (Applied Biosystems, Foster
City, CA). For each sample, 700 ng of RNA, 5μL master mix solution, and varying amounts of
nuclease-free DEPC-treated water were combined to reach a total volume of 20μL. GeneAmp
PCR system 9700 thermal cycler was used to convert the RNA to cDNA, with cycler conditions
of 25 °C for 5 minutes, 46 °C for 20 minutes, and 95 °C for 1 minute. The cDNA was diluted with
80μL of nuclease-free DEPC-treated water. 10μL of Power SYBR Green Master Mix (Applied
Biosystems, Foster City, CA) was added to 5μL of cDNA and 1μL of 10μM forward and reverse
primers (Integrated DNA Technologies, Coralville, IA) and loaded into a MicroAmp Fast 96 well
reaction plate. Real time quantitative PCR was performed using Applied Biosystems 7500 Fast
Real-Time PCR System. qRT-PCR was analyzed for ΔΔCq and the NCI-H441 control cells
cultured on 1 kPa plates were used as a control to determine the relative gene expression of the
NCI-H441 control 25 kPa, NCI-H441 shKRAS 1 and 25 kPa samples. The gene 18-S was used
as an internal control. The list of primers are as follows:
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E-Cadherin
Forward: GGAGCCAGACACATTTATGG
Reverse: CCGGATTAATCTCCAGCC
Vimentin
Forward: GCTAACCAACGACAAAGCC
Reverse:CCTCTCTCTGAAGCATCTCCTC
18-S
Forward: GCAATTATTCCCCATGAACG
Reverse: GGGACTTAATCAACGCAAGC

Statistical Analysis
Data is presented as mean +/- standard deviation. Graphpad Prism was used for statistical
analysis of the data, using One way ANOVA tests with Tukey pot-hoc comparisons for stiffness
comparisons, and Two way ANOVA tests with Tukey pot-hoc for stretch comparisons.
Significant differences were labeled as followed: * p-value < 0.05, ** p-value < 0.01, *** p-value
< 0.001, and **** p-value < 0.0001.
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Results
Primary cilia are present in KRAS-mutated NSCLC
KRAS-mutated NSCLC cell lines H358, H441, LU99, and H1792 were used for in vitro
immunofluorescence staining. The cells were plated on silicone stretch plates, with one plate
being held under static conditions, and one plate undergoing 15% cyclic stretch for 48 hours.
Cells were stained with DAPI, ARL13B, and α-acetylated tubulin, the co-localization of which
confirms the presence of primary cilia. The presence of primary cilia was found in the static
controls of H441, LU99, and H1792 cells, however no initial primary cilia were present in H358
cells (Fig. 14-15). When the cells were exposed to mechanical stretch, there was a significant
increase in the number of primary cilia for the lines that had primary cilia present statically.
Stretch of H358 cells initiated the formation of primary cilia, although there was not a significant
increase from static conditions (Fig. 13).

Figure 13: Quantification of increased primary cilia in stretched cells. Stretch of KRAS mutated NSCLC cells
caused significant increase in presence of primary cilia when primary cilia were initially present under static
conditions. Data is the percentage of ciliated cells out of the number of cells present. Two-way ANOVA with Tukey
post-hoc test. Data is representative of the mean +/- standard deviation, n=2 per group. **p<0.01, ***p<0.001.
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Figure 14: Stretch induces an increase in primary cilia. Cells were stretched for 48 hours, fixed, and stained for
DAPI (blue), ARL13B (red), and α-acetylated tubulin (green). A. KRAS G12C mutated bronchioalveolar carcinoma
cells (H358) under static conditions show no presence of primary cilia. B. KRAS G12C mutated bronchioalveolar
carcinoma cells (H358) under stretched conditions show presence of a few primary cilia around the periphery of cell
nuclei. C. KRAS G12V mutated papillary adenocarcinoma cells (H441) under static conditions show presence of
multiple primary cilia. D. KRAS G12V mutated papillary adenocarcinoma cells (H441) under stretch conditions show a
significantly increased presence of primary cilia.
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Figure 15: Stretch induces an increase in primary cilia. Cells were stretched for 48 hours, fixed, and stained for
DAPI (blue), ARL13B (red), and α-acetylated tubulin (green). A. KRAS G12C mutated lung giant cell carcinoma cells
(LU99) under static conditions show presence of a few primary cilia. B. KRAS G12C mutated lung giant cell
carcinoma cells (LU99) under stretched conditions show a significant increased presence of primary cilia around the
periphery of cell nuclei. C. KRAS G12C mutated adenocarcinoma cells (H1792) under static conditions show
presence of multiple primary cilia. D. KRAS G12C mutated adenocarcinoma cells (H1792) under stretch conditions
show a significantly increased presence of primary cilia.
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MEK inhibition affects the formation of primary cilia
Cell lines H441, LU99, and H1792 were held under static conditions and treated with
1μM of MEK inhibitor Trametinib for 48 hours (Fig. 17-18). Immunofluorescence staining for
primary cilia showed that the inhibition of MEK caused a significant decrease in the amount of
primary cilia formed (Fig. 16).

Figure 16: Quantification of decreased primary cilia with MEK inhibition. MEK inhibition of KRAS mutated
NSCLC cells caused significant decrease in presence of primary cilia. Data is the percentage of ciliated cells out of
the number of cells present. Two-way ANOVA with Tukey post-hoc test. Data is representative of the mean +/standard deviation, n=2 per group. *p<0.05, ****p<0.0001.
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Figure 17: Primary cilia formation decreased with MEK inhibition. Cells were fixed, and stained for DAPI (blue), ARL13B (red),
and α-acetylated tubulin (green). A. KRAS G12V mutated papillary adenocarcinoma cells (H441) under static conditions show
presence of multiple primary cilia. B. KRAS G12V mutated papillary adenocarcinoma cells (H441) under static conditions treated
with MEK inhibitor Trametinib show a significantly decreased presence of primary cilia.
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Figure 18: Primary cilia formation decreased with MEK inhibition. Cells were fixed, and stained for DAPI (blue),
ARL13B (red), and α-acetylated tubulin (green). A. KRAS G12C mutated lung giant cell carcinoma cells (LU99) under
static conditions show presence of a few primary cilia. B. KRAS G12C mutated lung giant cell carcinoma cells (LU99)
under static conditions treated with MEK inhibitor Trametinib show a significant decreased presence of primary cilia
around the periphery of cell nuclei. C. KRAS G12C mutated adenocarcinoma cells (H1792) under static conditions
show presence of multiple primary cilia. D. KRAS G12C mutated adenocarcinoma cells (H1792) under static
conditions treated with MEK inhibitor Trametinib show a significantly decreased presence of primary cilia
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KRAS silencing affects presence of primary cilia
H441 cells with tet-on control and shKRAS vectors were held at static and stretch
conditions for 48 hours (Fig. 20). As previously mentioned, there was primary cilia present in
control cells, and there was a significant increase in the number of primary cilia when the cells
undergo stretch. When shKRAS was activated through addition of doxycycline, there was no
longer primary cilia present, and stretch no longer significantly increased the number of primary
cilia (Fig. 19).

Figure 19: Quantification of primary cilia with KRAS silencing. Stretch of KRAS mutated G12V papillary
adenocarcinoma cells (H441) caused significant increase in presence of primary cilia. KRAS silencing caused
significant decrease in presence of primary cilia in static and stretched conditions. Stretched caused mechanical
activation of primary cilia formation when KRAS was silenced, but was significantly decreased compared to the
mechanical activation when KRAS was present. Data is the percentage of ciliated cells out of the number of cells
present. Two-way ANOVA with Tukey post-hoc test. Data is representative of the mean +/- standard deviation, n=2
per group. **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 20: KRAS silencing caused inhibition of primary cilia formation. KRAS G12V mutated papillary
adenocarcinoma cells (H441) were transfected with tet-on shKRAS vectors, stretched for 48 hours, fixed, and stained
with DAPI (blue), ARL13B (red), and α-acetylated tubulin (green). A. H441 control cells under static conditions show
presence of multiple primary cilia. B. H441 control cells under stretch conditions show a significantly increased
presence of primary cilia. C. H441 shKRAS cells under static conditions show complete inhibition of primary cilia
formation. D. H441 shKRAS cells under stretch conditions show the formation of primary cilia, but significantly
decreased from control cells under static and stretched conditions.
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Substrate stiffness influences morphology
H358 cells were seeded on soft and stiff substrates and examined under microscopy
after 48 hours (Fig. 21). It was seen visually that the morphology of the cells shifted towards a
more tumor-like sphere when exposed to the stiffer substrate, and through quantification it was
shown that the average size of tumor aggregates significantly increased with stiffness (Fig. 22).
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Figure 21: Microscopy images of substrate stiffness-Induced morphology changes. KRAS G12C mutated
bronchioalveolar carcinoma cells (H358) were seeded on 1 kPa and 25 kPa tissue culture plates for 48 hours.
Microscopy images were taken to examine changes in morphology that are associated with substrate stiffness. A. 1
kPa substrate stiffness shows normal cell morphology with a few cell aggregates. B. 25 kPa substrate stiffness shows
cells forming fused tumorsphere morphology.
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Figure 22: Average area of cell Aggregates or tumor-spheres. Images A and B from Figure 13 were quantified
using ImageJ and statistical analysis was performed in GraphPad. Each cell arrogate or tumorsphere area was
measured and the average was taken. Analysis shows significant increase in area of cells, showing that on increased
substrate stiffness there is a 5-fold increase in cell aggregation area. **** p<0.0001 for two-tailed Welch’s t-test.
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MEK inhibition with Trametinib leads to feedback upregulation of KRAS
The KRAS G12C mutated cell lines H358 and LU99 were cultured on soft and stiff
substrates, and treated with 1μM of the KRAS G12C inhibitor ARS1620 and 1μM of the MEK
inhibitor Trametinib. The same lysates that were used for the phospho-RTK array were also
immunoblotted to confirm the results found with the array. The cells that had been treated with
the MEK inhibitor were also blotted to compare against the KRAS G12C inhibitor. ARS1620 is a
KRAS G12C inhibitor that works by covalently targeting an allele-specific inducible allosteric
switch II pocket, which stops KRAS from switching to the active GTP-bound state. Although the
inhibition of KRAS-GTP specifically was not examined, there have been multiple studies that
showed in the same cell lines H358 and LU99 that 1μM ARS1620 for 48 hours completely
inhibited KRAS-GTP [49, 50]. Overall expression of KRAS was detected through western
blotting. The previous studies mentioned also showed that while KRAS-GTP was effectively
inhibited at 48 hours there was still p-ERK expression, which was also detected in our study as
well. MEK inhibition was confirmed through western blotting by examining the activation of
downstream protein ERK (Fig. 23). While treatment with 1μM Trametinib caused a complete
abolition of p-ERK, there was a significant increase in total KRAS due to feedback mechanisms.
Quantification was performed through ImageJ to confirm a significant decrease in protein
expression occurred (Fig. 23).
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Figure 23: Effect of KRAS and MEK inhibition on protein expression. A. 25μM of protein from lysates of KRAS G12C
mutated lung giant cell carcinoma cells LU99 and KRAS G12C mutated bronchioalveolar carcinoma cells H358 were analyzed
through western blotting for confirmation of drug effectiveness. B. Expression of KRAS and p-ERK was quantified through
ImageJ, and normalized to expression of loading protein B-actin. p-ERK expression was significantly inhibited through MEK
inhibitor Trametinib, and caused a significant increase in KRAS through feedback mechanisms. Data is normalized to 1 kPa
control for each cell line and is representative of the mean +/- standard deviation. One-way ANOVA with Tukey post-hoc test.
**p<0.01, ***p<0.001, ****p<0.0001.
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Phosphorylation of RTKs is significantly affected by substrate stiffness and
KRAS inhibition
The KRAS G12C mutated cell lines H358 and LU99 were cultured on soft and stiff
substrates, and treated with 1μM of the KRAS G12C inhibitor ARS1620 and 1μM of the MEK
inhibitor Trametinib. The no treatment and KRAS G12C inhibited cells were analyzed with a
phospho-Receptor Tyrosine Kinase array to determine the changes in activation that occurred
with increased substrate stiffness. The phospho-RTK array allows us to examine 49 different
phosphorylated human RTKs without performing numerous western blots. Antibodies for pan
phosphorylation are duplicated on nitrocellulose membranes for statistical analysis, with control
spots containing PBS for background subtraction. The layout of the membrane with the location
of the different phospho-RTK antibodies can be found in Appendix A, Figure 30. The membrane
images can be found in Appendix A, Figure 31. The relative expression was analyzed with
ImageJ and the phospho-RTKs that had a significant change with substrate stiffness were
plotted, with the soft substrate being used as the control for normalization. Protein expression
from the western blot was quantified using ImageJ, with the phospho-RTK expression being
normalized back to the loading control protein β-actin and compared to the soft substrate as a
control.

Phosphorylation of the Eph family
The Ephrin family, a group of proteins that bind to Eph receptors, is the largest of the
RTK families. Eph receptors are highly involved in development, but rarely detected in adult
tissue. Expression in adult tissue has been linked to solid tumor formation for multiple types of
cancer, and has been correlated to high malignancy and metastasis due to its role in cell
migration, angiogenesis, and EMT [51]. The phospho-RTK array probed for 10 out of 14 Eph
receptors, of these 10, phospho-EphA1, phospho-EphA2, phospho-EphB2 and phospho-EphB3
were detected in the KRAS G12C mutated NSCLC cell lines LU99 and H358 (Fig. 24).

41

The expression of phospho-EphA1 was not significantly affected by increased stiffness
in LU99 cells, but it was observed that there was a significant decrease in expression when
KRAS was inhibited on the stiff substrate, which did not occur on the soft substrate. In H358
cells, there was a significant decrease in expression when the substrate stiffness increased, and
there was a significant decrease when KRAS was inhibited on the stiff substrate. In both cell
lines there was a significant increase in phospho-EphA2 expression with increased stiffness. In
LU99 cells with KRAS inhibited through ARS1620 there was a significant increase on soft
stiffness, but when KRAS was inhibited on the stiff substrate there was a significant decrease
(Fig. 24). In H358 cells this increase on soft substrates did not occur, however there was a
significant decrease in the expression when KRAS was inhibited on the stiff substrate.
The expression of phospho-EphB2 decreased on stiff substrate for both cell lines, with
the decrease being significant for H358 cells. Expression decreased further when KRAS was
inhibited, regardless of substrate. The phospho-EphB3 expression was significantly decreased
with increased stiffness in H358 cells, with no significant change in LU99 cells. In H358 cells
with KRAS inhibited through ARS1620 there was a significant increase on soft stiffness which
did not occur when KRAS was inhibited on the stiff substrate. Overall, the Eph family of
receptors are affected by substrate stiffness, showing that they are mechanosensing their
environment. It is also shown that the Eph receptors are affected by KRAS inhibition, and for
some of the Eph receptors this affect is mechanically dependent.
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Figure 24: Quantification of Eph family expression. Expression of phosphorylation of Eph Family in LU99
and H358 cells detected through RTK array and quantified through ImageJ. A. Expression of p-EphA1 shows
significant decrease in expression when KRAS was inhibited on stiff substrates that did not occur on soft
substrates. B. Expression of p-EphA2 shows significant increase with substrate stiffness and decrease when
KRAS is inhibited on stiff substrates. C. Expression of p-EphB2 shows in H358 significant decrease in
expression with substrate stiffness. D. Expression of p-EphB3 shows in H358 a significant decrease with
substrate stiffness. Overall the Eph Family shows that there is an effect due to mechanical forces. Data is
normalized to 1 kPa control for each cell line, and is representative of mean +/- standard deviation, n=2 per
group. One way ANOVA with Tukey post-hoc test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Phosphorylation of the Insulin family
Insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF1R) are RTKs,
activated by insulin, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2).
Both receptors have been found to be involved in several cancers, including lung, by promoting
vascularization and invading apoptosis [52]. The expression of pan phospho-IGF1R and pan
phospho-IR significantly increased in both cell lines when substrate stiffness increased, and
while expression slightly increased when KRAS was inhibited on soft substrates, there was a
significant decrease in activation when KRAS was inhibited on stiff substrates (Fig. 25).
The combination of phosphorylation of IGF1R on tyrosine residue 1131 and
phosphorylation of Insulin receptor on tyrosine residue 1146 was able to be detected through
western blotting and quantified through ImageJ (Fig. 25). For the activation of IGF1R, three
tyrosine residues need to phosphorylated; Tyr1131, Tyr1135, and Tyr1136 [53]. For the
activation of IR, Tyr1146 and either Tyr1150 or Tyr1151 need to be phosphorylated, with full
activation of IR requiring all three tyrosine residues to be phosphorylated [54]. In both cell lines it
was confirmed that there was a significant increase with increase substrate stiffness and a
significant decrease in expression when KRAS was inhibited on the stiff substrate. Through
western blotting the effect of MEK inhibition was also examined, with the expression of
phospho-IGF1R/IR slightly increasing with MEK inhibition on the soft substrate, and slightly
decreasing on the stiff substrate.
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The expression of phospho-

Figure 25: Protein expression of p-IGF1R and p-IR. A. Expression of pIGF1R in LU99 and H358 cells detected through RTK array and quantified
through ImageJ. B. Expression of p-IR in LU99 and H358 cells detected
through RTK array and quantified through ImageJ. C. Expression of pIGF1R/IR was detected through western blot in LU99 and H358 cells using
the same lysates to confirm results. D. Quantification of protein expression
through western blot with ImageJ, Analysis shows significant increase of
expression with increased mechanical forces, and a decrease in expression
when KRAS was inhibited on stiff substrates that did not occur on soft
substrates, showing that there is a link between KRAS and mechanical
forces. One-way ANOVA with Tukey post-hoc test. Data is representative of
the mean +/- standard deviation, n=2 per group. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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Phosphorylation of EGFR and HGFR
EGFR is a member of the ErbB family of RTKs and is highly involved in many types of
cancer. Overexpression of EGFR is the second most common mutation in NSCLC, and causes
non-stop proliferation [55]. In LU99 cells, there was a significant increase of pan phospho-EGFR
with increased substrate stiffness (Fig. 26). When KRAS was inhibited on soft substrate, there
was a significant increase in expression, and a slight non-significant increase when KRAS was
inhibited on stiff substrate. In H358 cells there was no change with substrate stiffness or KRAS
inhibition on soft substrates. However, there was a significant decrease of pan phospho-EGFR
expression when KRAS was inhibited on stiff substrates. This exact trend was not detected
through western blotting, where specifically the phosphorylation of tyrosine 1068 was examined.
There was a small increase in expression when cell were exposed to stiffer substrates in both
cell lines, with the increase for H358 being significant. There was also a significant decrease of
expression when KRAS was inhibited on soft and stiff substrates for both cell lines, with a
greater decrease on the stiffer substrate. MEK inhibition in LU99 caused a slight but significant
decrease in the expression of phospho-EGFR at Tyr1068, and completely abolished the
expression of phospho-EGFR at Tyr1068 in H358. These effects were not stiffness dependent.
The differences in results seen between the RTK array and western blot is due to examination
of pan phosphorylation with the RTK array and specific tyrosine residue phosphorylation
through western blotting.
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Figure 26: Protein expression of p-EGFR and p-HGFR. A. Protein expression detected through RTK array and quantified
through ImageJ. B. Protein expression detected through western blot. C. Quantification of western blot through ImageJ.
Results from the RTK array varied from the western blot for p-EGFR expression. Expression of p-HGFR was only able to be
detected in H358 cells through western blot, which did confirm the results seen in the RTK array. One-way ANOVA with
Tukey post-hoc test. Data is representative of the mean +/- standard deviation, n=2 per group. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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HGFR, also known as c-Met, is involved in embryogenesis and tissue regeneration for
wound healing in adults. In cancer, HGFR up-regulation can cause angiogenesis, tumor growth,
and metastasis [56]. The expression of pan phospho-HGFR was significantly increase with
substrate stiffness, and with KRAS inhibition on soft substrates in both cell lines. When KRAS
was inhibited on stiff substrates there was a significant decrease in expression in H358 cells,
and there was no longer a significant increase in LU99 cells (Fig. 26). Expression of phosphoHGFR at tyrosine residues 1234 and 1235 increased with substrate stiffness, significantly
increased when KRAS was inhibited on soft substrate, and significantly decreased when KRAS
was inhibited on stiff substrate when the cell line H358 was detected through western blotting
(Fig. 26). Again, MEK inhibition completely inhibited the expression of phospho-HGFR
Tyr1234/1235. phospho-HGFR Tyr1234/1235 was unable to be detected in the LU99 cell line
through western blot. The differences in results seen between the RTK array and western blot is
due to examination of pan phosphorylation with the RTK array and specific tyrosine residue
phosphorylation through western blotting.
To help summarize the trends seen in RTK expression, Figure 27 and Figure 28 were
created in represent results in a graphical depiction. In Figure 27, the results of KRAS inhibition
on the mechano-activation of RTKs is shown. These results were seen for RTKs including
EphA2, IGF1R, IR, EGFR, and HGFR, and does not include results seen for EphA1, EphB2,
and EphB3. In Figure 28, the results of MEK inhibition on the mechano-activation of RTKs is
shown. This was only examined through western blotting, at specific tyrosine residues and not
pan phosphorylation. These results were seen for EGFR and HGFR for H358 cells. This trend
was not seen for IGF1R and IR, as MEK inhibition followed similarly to KRAS inhibition. This
trend was also not seen in EGFR for LU99 cells, where MEK inhibition had no effect on
phosphorylation of EGFR Tyr1068.
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Figure 27: RTKs sensing substrate stiffness with KRAS inhibition. Graphical depiction of results found with
EphA2, IR, IGF1R, EGFR and HGFR. A. Normal collagen crosslinking, representing normal lung ECM has normal
levels of phosphorylation of RTK. B. Normal collagen crosslinking, with KRAS inhibited leads to increased levels of
phosphorylation, possibly due to feedback mechanisms. C. Increased collagen crosslinking, representing cancerous
ECM causes an increase in phosphorylation. D. Increased collagen crosslinking, with KRAS inhibited causes a
decrease in phosphorylation of RTK. MEK inhibition had a similar effect on IGF1R phosphorylation.
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Figure 28: RTKs substrate stiffness with MEK inhibition. Graphical depiction of results found with EGFR and
HGFR for H358 cells. A. Normal collagen crosslinking, representing normal lung ECM has normal levels of
phosphorylation of RTK. B. Normal collagen crosslinking, with MEK inhibited leads to inhibition of phosphorylation. C.
Increased collagen crosslinking, representing cancerous ECM causes an increase in phosphorylation. D. Increased
collagen crosslinking, with MEK inhibited causes inhibition of phosphorylation of RTK. MEK inhibition had no effect on
EGFR phosphorylation in LU99 cells.
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KRAS plays a role in stiffness-induced EMT
The KRAS-mutated NSCLC lines LU99 and H358 were cultured on soft (1 kPa) and stiff
(25 kPa), tissue culture dishes, coated in collagen, in order to mimic normal lung ECM and
cancerous lung ECM. After 48 hours, protein was collected and a western blot was run to
confirm protein expression of EMT markers (Fig. 27). Quantification of the EMT marker protein
expression, performed in ImageJ, was normalized back to the loading control protein β-actin
and compared to the soft substrate as a control. The epithelial cell line H358 only expressed ECadherin, with no Vimentin expression detected. The mesenchymal cell line LU99 only
expressed Vimentin, with no E-Cadherin expression detected, therefore each cell line was only
analyzed for the respective EMT marker. Expression of epithelial marker E-Cadherin in H358
cells, significantly decreased with stiffness, indicating the cells underwent EMT. When KRAS
was inhibited with 1uM ARS1620, there was an increase of E-Cadherin on the soft substrate,
and an even larger fold increase of protein expression when KRAS was inhibited on the stiffer
substrate. The expression of mesenchymal marker Vimentin in LU99 cells significantly
increased with stiffness, also indicating EMT. When KRAS was inhibited, again there was a
decrease on the soft substrate, and an even further fold decrease of protein expression on the
stiffer substrate. This suggests that with the decreased presences of KRAS the cells no longer
underwent EMT. When MEK, which is downstream of KRAS, was inhibited with 1uM Trametinib
in H358 cells, there was a decrease of E-cadherin on the softer substrates, and an increase on
the stiffer substrates, comparable to when KRAS was inhibited. In LU99 cells there was a
decrease of Vimentin on the soft substrate when MEK is inhibited, and an even further decrease
when the cells are exposed to the stiffer substrate. This suggests that by inhibiting MEK, we are
again inhibiting the cells from undergoing EMT.
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Figure 29: KRAS inhibition stops stiffness-induced EMT. Western blot analysis was used to examine protein
expression of epithelial marker E-Cadherin and mesenchymal marker Vimentin. Quantification was performed
through ImageJ. It is shown in LU99 cells that Vimentin expression is significantly decreased with KRAS inhibition. In
H358 cells KRAS inhibition causes a significant increase in expression. One-way ANOVA with Tukey post-hoc test.
Data is representative of the mean +/- standard deviation, n=2 per group. ****p<0.0001.
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H441 cells with tet-on control and shKRAS vector were cultured on soft and stiff tissue
culture dishes. After 48 hours, RNA was collected to examine EMT marker gene expression
(Fig. 28). Control cells on the soft substrate were used as a control to compare gene expression
changes when cells are cultured on stiff ECM. When KRAS is present the stiffer, cancerous-like
substrate causes a decrease in E-Cadherin, an epithelial marker, and a significant increase in
Vimentin, a mesenchymal marker. When KRAS is knocked down, as shown through protein
expression, there is a significant increase in E-cadherin on soft substrates, indicating that the
cells are able to become more epithelial-like. When KRAS is knocked down and the cells are
exposed to the stiffer substrate, there is a significant decrease in E-Cadherin compared to the
soft, as well as a significant decrease in Vimentin compared to when KRAS is present. This
shows that the stiffness of the substrate causes a shift from epithelial to mesenchymal and that

H441 shControl
H441 shKRAS

when KRAS expression is silenced that this shift no longer occurs.

Figure 30: KRAS silencing stops stiffness induced EMT. Relative mRNA expression level of EMT markers in
H441 control and shKRAS cells, determined by qRT-PCR. With the presence of KRAS, cells underwent EMT when
exposed to increased substrate stiffness. When KRAS expression was silenced, there was a significant decrease in
Vimentin expression, showing the cells did not shift towards a mesenchymal phenotype. Western blotting shows the
decrease in KRAS expression, compared to the loading protein GAPDH. One-way ANOVA with Tukey post-hoc test.
Data is representative of the mean +/- standard deviation, n=3 per group. **p<0.01, ***p<0.001.
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Discussion
Lung cancer is the leading cause of cancer related deaths worldwide, with 80-85% of all
lung cancers falling in the category of NSCLC [1]. RAS, a molecule which hydrolyzes GTPases,
is the most commonly mutated gene family in cancer, and up-regulation causes over activation
in various pathways, including the MAPK signaling pathway. In NSCLC, the most common
oncogenic driver mutation is KRAS, which causes increased proliferation, migration, and
invasion [3]. In normal lung function, there are a variety of physical forces that causes stress,
including surface tension, shear strain from blood flow, as well as tension and compression from
breathing. In a normal healthy lung, cells have mechanisms that sense these forces through
mechanotransducers and this activates signaling pathways that aid in the homeostasis of the
tissue. Mechanosensing mechanism include primary cilia, integrins, receptor kinases, and ionchannels. In this study we examined two different types of mechanosensors, primary cilia and
RTKs, and how KRAS is intertwined in these mechanosensing mechanisms.

Primary cilia present in KRAS-mutated NSCLC
Primary cilia have been shown to transduce physical cues from the ECM to the cell;
however, their role in cancer varies between types of cancer and mutations present, with some
cancer types having a depletion of primary cilia, and some having an increase in primary cilia
[30]. In the lung it has been shown that primary cilia are present during development but as we
mature primary cilia are lost [27]. In NSCLC, primary cilia has not been extensively explored, but
it has been shown that overall there is an increase in the amount of primary cilia, including
KRAS mutated NSCLC lines, with a few mutations, such as EGFR, causing no primary cilia
formation [33]. In this study, we examined 4 KRAS mutated NSCLC cell lines through
immunofluorescence for the presence of primary cilia, and found that 3 out of 4 had a basal
level present under static conditions. Our data seems to agree with previous studies, that KRAS
mutated NSCLC lines have primary cilia present. In order to examine why H358 cells did not
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have any primary cilia detected, the mRNA expression of epithelial and mesenchymal markers
was examined using data from the Cancer Cell Line Encyclopedia (CCLE) (Fig. 29). It seems
that having only E-Cadherin or only Vimentin expression did not affect primary cilia formation,
but H358 cell line had almost equal amounts of both mRNA present. This effect of both
epithelial and mesenchymal marker expression on primary cilia formation may be an avenue to
explore further.

Figure 31: mRNA Expression of EMT Markers in NSCLC Lines from CCLE

It was also found that when all 4 cell lines were exposed to biaxial stresses under
biological conditions the amount of primary cilia increased in all 4 cell lines, with a significant
increase in 3 out of 4 cell lines. The cell line H358, which did not initially have primary cilia
detected, did not have a significant increase in primary cilia with mechanical stimulation. It is still
unknown whether tension is causing increased formation of primary cilia or if this is causing an
activation of dormant structures. The change in primary cilia detection with mechanical tension
applied could possibly be due to changes in signaling pathways involved in cilia formation, or
changes in intracellular trafficking pathways due to plasma membrane tension, and potential
mechanisms still need to be explored. While primary cilia are known to be mechanotransducers,
the effect of mechanical forces on ciliogenesis has not been widely examined. It has been
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shown that shear stress from fluid flow in human umbilical vein endothelial cells has caused
decrease in primary cilia, as well as the length of primary cilia to decrease in mouse kidney cells
[57,58]. Compressive forces have also been shown to cause decrease in the length and amount
of primary cilia present in chondrocytes [59], but the effect of tension is still relatively unknown.

MEK inhibition affects the formation of primary cilia
When MEK was inhibited under static conditions in the 3 cell lines that had primary cilia
present, it was found that the presence of primary cilia significantly decreased. It has been
found in PDAC, which has a loss of primary cilia with KRAS mutation, that disruption of
ciliogenesis boosts RAS–ERK signaling, showing that this pathway is correlated to the formation
of primary cilia [35]. In another study, it was found that specifically MAPK15 (ERK7/8) is
necessary for the formation of primary cilia in human cells. ERK7/8 was found localized at the
basal body and regulated the localization of proteins necessary for cilium structure, transport,
and signaling [60]. It was shown in NSCLC lines that had de novo resistance to MEK inhibition
through Trametinib that there was an increase in length and number of primary cilia compared
to non-resistant lines [33]. Our findings show that the MAPK pathway is necessary for primary
cilia formation in KRAS mutated NSCLC, and are consistent with other literature in that the
MAPK pathway plays a role in ciliogenesis.

KRAS silencing affects presence of primary cilia
When KRAS was silenced through tet-induced shRNA in the cell line H441, it was found
that primary cilia were no longer detected under static conditions, compared to the H441 with
the tet-induced control vector. When the H441 shKRAS cells underwent stretch, there was a
significant decrease in the amount of primary cilia compared to the H441 shControl cells, but
there were now primary cilia detected. This indicates that KRAS plays a role in primary cilia
formation and without KRAS, the significant increase of primary cilia through mechanical
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activation no longer occurs. Whether or not KRAS specifically is playing a role in the mechanical
induction of primary cilia needs to be further explored. In pancreatic ductal adenocarcinomas
the mutation of KRAS caused a loss of primary cilia, and through inhibition of KRAS, there was
a reformation of primary cilia [34, 35]. As stated previously, it has been shown that KRAS
mutated NSCLC has a gain of primary cilia, and it stands to reason that through inhibition of
KRAS there would be a decrease in primary cilia present.

Substrate stiffness influences morphology
It is known that healthy lung has an ECM stiffness of 1 kPa, however when cancerous
cells form solid tumors the surrounding ECM stiffness increases anywhere from 20 kPa to 100
kPa [39]. To first see if the cells were affected by increased ECM stiffness, the cell line H358
was seeded on soft and stiff substrates and examined under microscopy to observe
morphological changes. It was seen that on the stiff substrate, the cells had formed tumor like
spheres. On the soft substrate individuals cells and aggregated cells were present, but with the
aggregated cells individual cells were still visible. On the stiff substrate there were larger,
circular formations, and in the tumor-spheres the cells begin to appear fused together. To
quantify this visualization, the cell aggregate and tumorsphere area was measured in ImageJ.
These changes with stiffened substrate suggest that it may be the stiffened ECM that promotes
tumor morphology.

Phosphorylation of RTKs is significantly affected by substrate stiffness and
KRAS inhibition
The other mechanosensor examined in this study was receptor tyrosine kinases, a
family of cell surface receptors that initiate pathways involved in proliferation, differentiation and
motility. It has been shown that RTKs are directly linked to sensing mechanical forces. It has
been found in fibroblast that the silencing of RTKs AXL and ROR2 altered the ability of the cells
to sense the rigidity of their substrate and consequently affected morphogenetic processes [48].
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RTKs also play a large role in cancer, with up-regulation being linked to EMT, cell survival, drug
resistance, invasion, and metastasis in several cancers. We also know that when RTKs activate
the MAPK pathway, they need to recruit RAS, and many RTKs have been linked to KRAS.
Increased ECM stiffness that is associated with cancer can cause an increased
activation of mechanosensors, which can lead to up-regulation of oncogenic pathways. In order
to explore how the activation of RTKs play a role in NSCLC, and how mechanosensing might be
linked to KRAS, 2 KRAS mutated NSCLC cell lines were seeded on soft and stiff matrices and a
phospho-RTK array was used to examine multiple RTKs at once. It was found that many RTKs
were activated through phosphorylation. The RTKs that were affected by increased substrate
stiffness and affected by KRAS inhibition in both cell lines were analyzed. It was found that
phosphorylation of members of the Eph family, EphA1, EphA2, EphB2 and EphB3, members of
the insulin family, insulin receptor, and IGF1R, EGFR, and HGFR were significantly affected.

Phosphorylation of the Eph family
The Eph family of RTKs is the largest, however it has not been thoroughly explored in
lung cancer. In NSCLC, Eph receptors have been shown to be involved in cancer progression
due to crosstalk with oncogenic signaling pathways. Specifically, EphA2 mutations have been
found to be increased in NSCLC harboring KRAS mutations, causing increased cancer cell
invasion and survival. When EphA2 expression was knocked down, it was found that there was
a decrease in cell proliferation and migration through increased ERK1/2 activation [61]. We
found that the expression of phospho-EphA2 increased with substrate stiffness. In both cell lines
there was an increase in expression when KRAS was inhibited on soft substrates, but there was
a decrease in expression when KRAS was inhibited on stiff substrates. The increased
expression with substrate stiffness suggests that stiffened ECM could play a role with EphA2
expression and increased cell invasion in NSCLC. These results may also show that KRAS
plays a role in the substrate stiffness induced increased expression. The increased expression
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when KRAS is inhibited on soft stiffness’ is likely due to feedback mechanisms, however the
suggestion that this does not occur on the tumor-like stiffness may show that KRAS is linked to
the mechanical activation.
The phosphorylation of Eph receptor EphA2 had the highest expression of all the Eph
receptors detected. Phosphorylation of all other Eph family receptors detected were only
significantly affected by increased stiffness in one cell line, H358, with the increased substrate
stiffness actually causing a decrease in expression. It has been reported in multiple cancer
types that expression of these receptors can be paradoxical. Expression can be either
increased or decreased depending on other mutations, cancer type, and stage of development.
In a global evaluation of Eph receptors in NSCLC, it was found that EphA1, EphB2, and EphB3
were down-regulated in NSCLC compared to normal bronchial epithelial cells [62]. This may
explain why the increased tumor-like stiffness caused a decrease in expression. EphA1, EphA2,
and EphB2 have all been linked to KRAS and to increased migration and invasion in KRAS
mutated lines compared to wild type [63,64], and we found that inhibiting KRAS caused a
decrease in expression. The expression of EphB3 has not been linked to KRAS in other studies,
and we found that phosphorylation was not affected by KRAS inhibition.

Phosphorylation of the Insulin family
The insulin family of receptors is known to play a role in growth and metabolism in
normal cell function, and up-regulation in cancer can lead to differentiation, proliferation, EMT,
and survival. Insulin receptor (IR) and IGF1R have been examined in relationship to KRAS in
NSCLC, and it was found that in KRAS mutated lines the inhibition of these receptors caused
tumor suppression in a mouse model of [65]. It has also been shown that in KRAS mutant
NSCLC, IGF1R activity caused activation of the PI3K pathway, but this did not occur in KRAS
wild type lines [66]. It has been found that activation through phosphorylation of insulin
receptors has been affected by substrate stiffness in adipocytes [67]. The expression of
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phospho-IR and phospho-IGF1R significantly increased with increased substrate stiffness.
There was a slight increase when KRAS was inhibited on soft substrates, and a significant
decrease when KRAS was inhibited on stiff substrates. The expression of phospho-IGF1R was
able to be confirmed through western blotting as well. This follows the same trend observed with
the phospho-RTK array that increased stiffness causes increased activation of the RTK, and
that KRAS inhibition played a role in this mechanical activation. Through western blotting we
were also able to examine the effect of MEK inhibition. It was found that MEK inhibition in both
cell lines caused an increase in phospho-IGF1R expression on the soft substrates and a
decrease on the stiff substrates, showing the same trend as KRAS inhibition. Our data from this
study correlates to other literature in that we found the insulin family of receptors to be affected
by substrate stiffness and to be linked to KRAS activity.

Phosphorylation of EGFR
EGFR is the second most common mutation in NSCLC, and is known to be a difficult
therapeutic target. In NSCLC it has been shown that cell invasion is driven by EGFR signaling
that is activated through ECM dependent mechanosensing [68]. In this study, the expression of
phospho-EGFR when examined through the phospho-RTK array was not the exact same trend
as found through western blotting. When the expression of phospho-EGFR was confirmed
through western blotting it was seen that inhibition of KRAS had a greater effect on stiffer
substrates. While the MEK inhibitor did not have any effect on the cell line LU99 it had equally
effective responses on soft and stiff substrates in H358 cells. It seems that this data follows the
same trend that has been found in other studies, that phospho-EGFR signaling was affected by
substrate stiffness. The differences in results seen between the RTK array and western blot is
due to examination of pan phosphorylation with the RTK array and specific tyrosine residue
phosphorylation through western blotting. It has been shown that EGFR residues Tyr1148 and
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Tyr1173 phosphorylation activates MAPK signaling [69], and these specific tyrosine sites may
need to be further examined.

Phosphorylation of HGFR
HGFR, or c-MET, is also known to be a larger player in oncogenesis, with HGFR
mutations being one of the most common in NSCLC. Up-regulation is known to cause increased
proliferation, invasion, metastasis, and cell survival, and HGFR is known to activate the
RAS/MAPK pathway [56]. It has also been shown that HGFR activation can be directly
influenced by ECM biomolecular makeup and stiffness [70, 71]. The expression of phosphoHGFR followed the trend of significantly increasing with substrate stiffness, significantly
increasing with KRAS inhibition on soft substrate and significantly decreasing with KRAS
inhibition on stiff substrates in both cell lines. While phosphorylation of HGFR at tyrosine
1234/1235 could not be detected through western blotting in the cell line LU99, the same trend
was confirmed in the cell line H358. MEK inhibition was effective on all stiffnesses. Our findings
are similar to other studies that found HGFR activation to be affected by substrate stiffness.
While MEK inhibition did not seem to be stiffness dependent, KRAS inhibition did, which may
indicate that KRAS specifically plays a role in mechanically induced activation.

KRAS plays a role in stiffness-induced EMT
The increased ECM stiffness in cancer, as well as the expression of KRAS and RTKs
have been linked in various cancers to EMT. To examine this effect we used the same two cell
lines from the phospho-RTK and immunoblotting to determine the effect of KRAS in substrate
stiffness induced EMT. The epithelial marker, E-Cadherin, could not be detected in the cell line
LU99 through western blotting, and in Fig. 29 it is seen that this cell line has a negligible amount
of E-Cadherin mRNA. Increased substrate stiffness caused a significant increase in Vimentin
expression, while KRAS inhibition caused a decrease on the soft substrate and an even further
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decrease on the stiff substrate. The mesenchymal marker, Vimentin, could not be detected in
the cell line H358 through western blotting. As shown in Fig. 29 this cell line does have Vimentin
mRNA present, but compared to LU99, which it was blotted next to, it has a significantly lower
expression, which could explain the lack of detection through western blot. The expression of ECadherin was significantly decreased with increased substrate stiffness, and slightly decreased
with KRAS inhibition on stiff substrates. This shows that while KRAS inhibition was effective at
normal lung stiffness it was even more effective on the tumor-like stiffness, showing that it could
be further activated through mechanosensing forces. MEK inhibition was effective on all
stiffnesses.
To further confirm the effect of KRAS in mechanically induced EMT, the cell line H441
with tet-on silencing of KRAS was seeded on soft and stiff substrates and EMT marker gene
expression was examined through qRT-PCR. It was found that in the H441 shControl cells,
there was a slight decrease in E-Cadherin expression, and a significant increase in Vimentin
expression. When KRAS was knocked down in the H441 shKRAS cells, there was a significant
increase in E-Cadherin and a slight decrease in Vimentin compared to the control cell on the
soft substrate, indicating that without KRAS the cells became more epithelial-like. When the
H441 shKRAS cells were seeded on the stiff substrate, the expression of E-Cadherin was
reduced, but was not significantly affected compared to the H441 shControl cells, and the
expression of Vimentin was significant decreased compared to the increase that was seen when
the control cells were exposed to the stiff substrate. This indicates that while the control cells
underwent stiffness induced-EMT, when KRAS expression was suppressed this transition no
longer occurred. KRAS is known to be a large player in EMT in NSCLC [41-44], and ECM
stiffness is known to induce EMT [70]; however, the link between the two has not been
thoroughly explored. In one study, it was shown that YAP1 and KRAS converged to regulate
EMT in response to elevated matrix stiffness in lung cancer [44]. Our findings are also showing
that KRAS can play a role in ECM stiffness-induced EMT.
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Conclusion
Primary cilia and receptor tyrosine kinases are mechanisms through which the cell
senses mechanical forces. KRAS mutations have been shown in multiple studies to be linked to
an increase in these mechanosensors, and subsequently a poor prognosis due to an increase in
proliferation, invasion, and EMT. In this study, we show that in KRAS mutated NSCLC there are
a multitude of active mechanosensors whose activation increased with increased mechanical
force. These include primary cilia, EphA2, IR, IGF1R, and HGFR. We also show that without the
expression of KRAS the increased mechanical forces no longer caused an increased activation.
In most cases when KRAS was inhibited on the normal lung ECM substrate there was no
significant change, or even an up-regulation due to feedback mechanisms. When KRAS was
inhibited on the stiffened tumor-like ECM substrate and the biologically relevant stretched
matrix, there was a decrease in expression of mechanoreceptors. This stiffness dependent
phenomenon was also seen in another study, which showed that there was a threshold between
15-28 kPa where KRAS protein levels had a mechano-sensitive response [41]. KRAS may be a
main player in mechanically activating mechanosensors, but whether its mechanism is direct or
indirect still needs to be explored.
We also explored the connection between KRAS mutations and ECM induced EMT
through the inhibition of KRAS with ARS1620 and through gene silencing with a tetracycline
inducible vector. It was found in multiple KRAS mutated NSCLC lines that increased ECM
stiffness caused EMT, and with decreased KRAS expression this phenomenon no longer
occurred.
Not only did this study explore the role of KRAS in mechanosensing but it also gave us
data on how affective KRAS and MEK inhibitors are in KRAS mutated NSCLC, and how this
may be affected by substrate stiffness. One large take away from this study is that the KRAS
G12C inhibitor, ARS1620, can be a potent alternative to other therapeutic options for KRAS
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mutated cancers. ARS1620 directly targets mutated KRAS and could lead to less off target
effects than the MEK inhibitor Trametinib. Also for cancers with signaling adaptation, ARS1620
could be an effective combination therapy.

Future Directions
Observing the presence of primary cilia in more KRAS NSCLC lines would allow us to
determine if this is a larger pattern. Also, examining if KRAS mutated NSCLC have a higher
presence of primary cilia than other non-KRAS mutated NSCLC lines to determine if specifically
KRAS increases the presence of primary cilia in NSCLC. The effect of KRAS gene silencing
was examined on primary cilia, however ARS1620 could also be used to look at the effect of
KRAS inhibition. This data could all be compared to the effect that KRAS inhibition has on
normal lung epithelial cells and the presence of primary cilia.
While the initial phospho-RTK data is helpful to begin to examine the effects of stiffness
on RTK activation, with the acquiring of funding, it would be possible to examine more cell lines
under RTK array analysis, and determine if the same receptors are affected across multiple
KRAS mutated NSCLC lines. These up-regulated receptors could also be examined under qRTPCR and western blot analysis to confirm. Antibodies for all specific tyrosine residues could be
obtained to examine further as to how RTK activation and KRAS are interrelated. One assay
that could be used to confirm that KRAS is indeed a key player in mechanosensing for these
receptors would be an immunoprecipitation to pull down and compare what proteins are being
activated on soft and stiff substrates.
The initial examination of stiffness induced EMT in KRAS mutated NSCLC has allowed
us to begin to examine the necessity of KRAS for these cells to undergo this process. To further
examine how KRAS plays a role in the poor prognosis of NSCLC, migration and invasion assay
could be performed to see if KRAS and stiffness induced EMT play a role in these
phenomenon’s. For all experiments a time point of 48 hours was used for KRAS inhibition. It has
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been seen that at this time point there is a re-upregulation of downstream proteins such as
phospho-ERK. In other studies it has been shown that at time points such as 6 hours and even
up to 24 hours this is not occurring. Moving forward a shorter time point may be examined.
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Appendix A

A

B

Figure 32: Human phospho-RTK array coordinates and corresponding antibodies [73]. A. Coordinates of
human phospho-RTK array. B. Corresponding receptor family and RTK for coordinates.
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D

Figure 33: H358 and LU99 phospho-RTK membrane images. A. H358 full membrane. Upper left image is H358
cells seeded on 1 kPa substrates. Lower left image is H358 cells seeded on 1 kPa substrates treated with ARS1620.
Upper right image is H358 cells seeded on 25 kPa substrates. Lower left image is H358 cells seeded on 25 kPa
substrate treated with ARS1620. B. H358 membrane overexposed and zoomed in to examine spots B5-B20, C5-C20,
D5-D20, E5-E20, and F5-F8. C. LU99 full membrane. Upper left image is LU99 cells seeded on 1 kPa substrates.
Lower left image is LU99 cells seeded on 1 kPa substrates treated with ARS1620. Upper right image is LU99 cells
seeded on 25 kPa substrates. Lower left image is LU99 cells seeded on 25 kPa substrate treated with ARS1620. D.
LU99 membrane overexposed and zoomed in to examine spots B5-B20, C5-C20, D5-D20, E5-E20, and F5-F8.
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